2024/01/01 by Katty Zeven, Yoline Lauwers, Lynn De Mey +4 · 1 voice
Medicine · #Monoclonal and Polyclonal Antibodies Research #Radiopharmaceutical Chemistry and Applications #Cancer Immunotherapy and Biomarkers
paper · pdf · doi:10.1093/immadv/ltae006
openalex publication_date 2024/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/04
The evolving landscape of cancer immunotherapy has revolutionized cancer treatment. However, the dynamic tumor microenvironment has led to variable clinical outcomes, indicating a need for predictive biomarkers. Noninvasive nuclear imaging, using radiolabeled modalities, has aided in patient selection and monitoring of their treatment response. This approach holds promise for improving diagnostic accuracy, providing a more personalized treatment regimen, and enhancing the clinical response. Nanobodies or single-domain antibodies, derived from camelid heavy-chain antibodies, allow early timepoint detection of targets with high target-to-background ratios. To date, a plethora of nanobodies have been developed for nuclear imaging of tumor-specific antigens, immune checkpoints, and immune cells, both at a preclinical and clinical level. This review comprehensively outlines the recent advancements in nanobody-based nuclear imaging, both on preclinical and clinical levels. Additionally, the impact and expected future advancements on the use of nanobody-based radiopharmaceuticals in supporting cancer diagnosis and treatment follow-up are discussed.